Abstract
Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.
| Original language | English (US) |
|---|---|
| Journal | The Lancet Infectious Diseases |
| DOIs | |
| State | Accepted/In press - Jan 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Infectious Diseases
Cite this
Development of vaccines against Zika virus. / Poland, Gregory A.; Kennedy, Richard B; Ovsyannikova, Inna G.; Palacios, Ricardo; Ho, Paulo Lee; Kalil, Jorge.
In: The Lancet Infectious Diseases, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Development of vaccines against Zika virus
AU - Poland, Gregory A.
AU - Kennedy, Richard B
AU - Ovsyannikova, Inna G.
AU - Palacios, Ricardo
AU - Ho, Paulo Lee
AU - Kalil, Jorge
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.
AB - Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.
UR - http://www.scopus.com/inward/record.url?scp=85041608916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041608916&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(18)30063-X
DO - 10.1016/S1473-3099(18)30063-X
M3 - Article
C2 - 29396004
AN - SCOPUS:85041608916
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
SN - 1473-3099
ER -